Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.38 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29596165 | 1.00 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL29596689 | 1.00 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL31240230 | 1.00 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL9154269 | 1.00 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL11880727 | 1.00 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL1534917 | 1.00 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL9152747 | 1.00 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL330429 | 1.00 | — | — | |
| SCHEMBL11691906 | 1.00 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL29596306 | 1.00 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM4CPHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| CN-101094827-B | Benzene compound having two or more substituents | DAIICHI SANKYO CO LTD | 2012-06-13 | — | — | CN | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| EP-1315733-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-04 | — | — | EP | disclosed |
| EP-1187820-A1 | SUBSTITUTED UREAS | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-20 | — | — | EP | disclosed |
| WO-2002020531-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001000602-A1 | SUBSTITUTED UREAS | BASF AKTIENGESELLSCHAFT (DE) | 2001-01-04 | — | — | WO | disclosed |
| EP-0398155-B1 | Cyclopropylalkyl or cycloalkenyl compounds, process for their preparation and their use in liquid crystal mixtures | HOECHST AG (DE) | 1996-02-07 | — | — | EP | disclosed |
| US-5407599-A | Cyclopropylaklyl or -alkenyl or heterocyclic compounds, process for their preparation and their use in liquid-crystalline mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-18 | — | — | US | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0398155-A2 | Cyclopropylalkyl or cycloalkenyl compounds, process for their preparation and their use in liquid crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-11-22 | — | — | EP | disclosed |
| US-3993773-A | Control of mites with esters of cyclopropane substituted carboxylic acids | ZOECON CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
| US-3960907-A | MITICIDES | ZOECON CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | SIGMAR1 1279/4885KDM5A 3756/4885KDM4C 4731/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | SIGMAR1 698/4885KDM5A 3027/4885KDM4C 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.